Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cells for CKD: Can They Help Reduce Inflammation?
Transcript
- 0:00SPEAKER_00: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_00: Imagine your body contains a microscopic, highly advanced water filtration plant.
- 0:08SPEAKER_01: And it works flawlessly for decades, you know, silently processing waste and keeping the entire system balanced.
- 0:14SPEAKER_00: Yeah, but then a quiet, invisible fire starts burning inside the facility.
- 0:20SPEAKER_00: It doesn't just destroy the building overnight, but it um it slowly melts the delicate machinery.
- 0:26SPEAKER_00: By the time you notice the smoke or actually see the functional damage, the system is already largely beyond repair.
- 0:32SPEAKER_01: Aaron Ross Powell That invisible fire is persistent inflammation.
- 0:35SPEAKER_01: And the filtration plant is, well, it's your kidneys.
- 0:38SPEAKER_00: Aaron Powell So on this deep dive, we are examining the current evidence behind regenerative approaches for chronic kidney disease or CKD.
- 0:46SPEAKER_00: The primary question driving this research is whether cellular treatments can actually calm that persistent inflammation before it permanently damages the kidneys.
- 0:55SPEAKER_01: Aaron Powell The science occurring in the laboratory is fascinating, really, but we must establish from the very beginning that the clinical reality for patients today is early, it is completely unproven, and strictly experimental.
- 1:08SPEAKER_00: Aaron Powell We have a pretty robust stack of sources guiding our exploration today.
- 1:14SPEAKER_00: We are looking at a massive 2025 review published in the journal CELS, comprehensive epidemiological data from the Lancet, and the established clinical guidelines from the National Institute of Diabetes and Digestive and Kidney Diseases, the NIDDK.
- 1:29SPEAKER_01: Aaron Ross Powell So our mission is to sort the biological promise from the clinical reality.
- 1:33SPEAKER_00: Aaron Powell And to set our terminology, we are looking at the experimental stem cell therapies being researched right now.
- 1:39SPEAKER_00: I mean, to understand the urgency of this research, you really have to understand the sheer scale of the condition first.
- 1:45SPEAKER_01: Aaron Powell You do.
- 1:46SPEAKER_01: The Global Burden of Disease Study, which was published in the Lancet in 2020, provides the epidemiological baseline.
- 1:53SPEAKER_01: Their data shows that in 2017 there were 697.5 million cases worldwide.
- 1:58SPEAKER_01: Aaron Ross Powell, Jr.
- 1:58SPEAKER_00: Which is that represents about 9.1% of the global population.
- 2:02SPEAKER_01: Aaron Powell Nearly 700 million cases.
- 2:05SPEAKER_00: Aaron Powell That is roughly one in every 11 people walking the planet, dealing with a condition that um often goes completely unnoticed in its earliest stages.
- 2:14SPEAKER_01: It is a staggering global health burden.
- 2:16SPEAKER_01: To comprehend what is actually happening inside the bodies of those individuals, we have to look at the mechanical breakdown caused by the disease.
- 2:24SPEAKER_00: Because CKD is a long-term progressive condition where the kidneys slowly lose their ability to filter waste from the blood.
- 2:32SPEAKER_01: Yes.
- 2:32SPEAKER_01: And the biological driver of this progression is that persistent inflammation.
- 2:37SPEAKER_01: Ongoing immune signals constantly injure the tiny, really intricate blood vessels inside the kidney.
- 2:43SPEAKER_00: Aaron Powell And this unending injury pushes the delicate filtering tissue to scar.
- 2:47SPEAKER_00: That scarring is the permanent damage.
- 2:50SPEAKER_01: The medical term for that scarring is fibrosis.
- 2:53SPEAKER_01: Fibrosis replaces highly specialized functional filtering cells with stiff, rigid collagen.
- 2:59SPEAKER_00: Aaron Powell Returning to the filtration plant analogy, if you do not put out that continuous low-grade fire of inflammation, the delicate machinery simply melts into useless scar tissue.
- 3:10SPEAKER_01: The tissue simply cannot perform its intricate filtering job once it becomes fibrotic scar tissue.
- 3:15SPEAKER_00: And eventually the damage becomes so widespread that the whole plant just shuts down.
- 3:20SPEAKER_01: That fibrosis fuels the disease progression toward complete kidney failure, which is also known as renal failure.
- 3:27SPEAKER_01: At that point, the body requires artificial filtration, like dialysis, just to survive.
- 3:32SPEAKER_00: Wait, hold on.
- 3:33SPEAKER_00: If we know that the smoldering fire of inflammation is the root cause of the fibrosis, how do doctors actually know the building is burning before it collapses?
- 3:42SPEAKER_01: Well, standard medical care does not directly measure the fire.
- 3:45SPEAKER_01: Instead, doctors use routine tests to track the functional fallout of the damage.
- 3:50SPEAKER_00: So they are measuring the debris and the failing systems?
- 3:52SPEAKER_01: Pretty much.
- 3:53SPEAKER_01: One primary metric is blood creatinine.
- 3:56SPEAKER_01: Creatinine is a continuous waste product generated by normal muscle breakdown.
- 4:01SPEAKER_01: As the kidney's filtering slows down, it fails to clear that waste efficiently.
- 4:05SPEAKER_00: Causing creatinine levels to rise in the blood.
- 4:08SPEAKER_00: It is a measure of the backup in the system?
- 4:10SPEAKER_01: Precisely.
- 4:11SPEAKER_01: They also calculate the estimated glomerular filtration rate, or EGFR.
- 4:16SPEAKER_01: This is not a direct measurement, but rather a score calculated using that blood creatinine number, factored alongside the patient's age and sex.
- 4:24SPEAKER_00: It provides an estimate of how well the kidneys are filtering per minute.
- 4:27SPEAKER_01: And finally, standard care tests for albumin in the urine.
- 4:31SPEAKER_01: Albumin is a large protein that belongs in the bloodstream.
- 4:35SPEAKER_01: The healthy kidney filter acts like a fine sieve, keeping large proteins inside the body while letting tiny waste molecules out.
- 4:42SPEAKER_00: So finding albumin in the urine indicates that the sieve is torn and leaking.
- 4:48SPEAKER_01: Yes, it is a key indicator of structural damage.
- 4:51SPEAKER_00: But that seems entirely backward from a preventative standpoint.
- 4:54SPEAKER_00: I mean, if we know the underlying problem is the fire, why are doctors waiting around checking for puddles on the floor, the leaky albumin, instead of installing a smoke detector to measure the fire itself during a routine checkup.
- 5:06SPEAKER_01: You are identifying the major divide between standard clinical care and laboratory research there.
- 5:12SPEAKER_01: Doctors track the functional clinical fallout, the leaking pipes and the backed up waste, because those tests are standardized.
- 5:19SPEAKER_01: They are widely accessible, reliable, and they dictate immediate proven treatment decisions.
- 5:25SPEAKER_00: Aaron Powell Whereas tracking the underlying biochemical mechanisms, such as measuring specific inflammation markers like interleukin 6 is complex and highly variable.
- 5:34SPEAKER_01: Aaron Ross Powell Highly variable.
- 5:35SPEAKER_01: Those markers are mostly utilized by research teams to see what is happening at the cellular level.
- 5:40SPEAKER_01: They simply are not practical or actionable for an everyday doctor visit.
- 5:44SPEAKER_00: Aaron Ross Powell If the researchers are the ones using the smoke detectors, that leads us directly into how those researchers are trying to actually enter the building and put out the fire.
- 5:53SPEAKER_00: This brings us to mesenchymal cells.
- 5:56SPEAKER_01: Aaron Ross Powell And we really must clarify a pervasive misconception about these cells.
- 6:00SPEAKER_01: The assumption is often that mesenchymal cells act as biological building blocks, that they are directly transforming into new healthy kidney tissue or physically replacing the dead fibrotic cells.
- 6:12SPEAKER_00: Aaron Powell But they do not function that way.
- 6:14SPEAKER_01: Aaron Powell No, they don't.
- 6:14SPEAKER_00: So they are not replacing the damaged filters.
- 6:17SPEAKER_00: They are not the bricks being used to rebuild the broken water filtration plant.
- 6:22SPEAKER_01: Aaron Ross Powell They operate through a completely different mechanism called pericrine signaling.
- 6:26SPEAKER_01: Rather than becoming part of the structure, they act by releasing chemical messengers, cytokines, and growth factors, into the surrounding tissue environment.
- 6:35SPEAKER_00: Their function is to protect the existing kidney cells that are still surviving.
- 6:40SPEAKER_01: Aaron Ross Powell To protect them, to support the repair of the small blood vessels, and most importantly for this discussion, to alter the immune response and reduce the inflammation.
- 6:51SPEAKER_00: Aaron Ross Powell So they are more like the site formen.
- 6:54SPEAKER_00: They show up to the biological job site with a bullhorn, handing out new blueprints, and instructing the chaotic inflamed environment to calm down, stop the immune attack, and start repairing the local blood vessels.
- 7:07SPEAKER_01: Aaron Powell The Formin analogy perfectly captures the essence of pericrine signaling.
- 7:11SPEAKER_01: They manage the local cellular environment rather than becoming the raw building materials themselves.
- 7:17SPEAKER_00: And researchers test several different cell sources to find the most effective formin, right?
- 7:22SPEAKER_00: Because results from one type do not automatically translate to another.
- 7:25SPEAKER_01: That is a crucial point.
- 7:27SPEAKER_01: In the human trials we will review, bone marrow is the most common source utilized.
- 7:32SPEAKER_01: However, labs can also isolate and expand mesenchymal cells from donated umbilical cord tissue.
- 7:38SPEAKER_00: As an example of this specific approach out in the real world, Cirona cell is a regenerative medicine center that utilizes Wharton's jelly mesenchymal stem cells, derived specifically from umbilical cord tissue, serving international patients who are exploring these experimental avenues.
- 7:54SPEAKER_01: And beyond utilizing whole cells, researchers are increasingly studying the physical packages those foreman use to deliver their instructions.
- 8:02SPEAKER_00: These are called cell sacs, vesicles, or exosomes.
- 8:05SPEAKER_01: Yes.
- 8:06SPEAKER_01: They're tiny messenger packages released by the cells filled with the chemical signals we discussed.
- 8:11SPEAKER_01: One of the human trials even infused these isolated packages derived from cord blood cells instead of administering whole living cells.
- 8:19SPEAKER_00: The concept of cellular foremen arriving with chemical bullhorns to put out the fire sounds incredibly promising in biological theory.
- 8:27SPEAKER_00: But the real question is whether they actually work on a living job site.
- 8:31SPEAKER_00: Let's look at the hard data from the 2025 review in the journal Cells.
- 8:35SPEAKER_01: The filtering process for this review is highly revealing about the state of the evidence.
- 8:40SPEAKER_01: The researchers initially searched through an extensive pool of 2,514 records.
- 8:46SPEAKER_00: Out of that massive pile of literature, they applied strict criteria and chose exactly 52 studies to analyze in depth.
- 8:53SPEAKER_01: They discarded thousands of records to find just 52 studies that were scientifically robust enough for their analysis.
- 8:59SPEAKER_01: And the data within those 52 selected studies is heavily skewed between controlled animal models and human patients.
- 9:07SPEAKER_00: The vast majority were animal studies, 49 in total, mostly conducted in rats.
- 9:13SPEAKER_01: And in these rat models of kidney injury, the administration of the cells successfully accomplished the goal.
- 9:18SPEAKER_01: They lowered two key inflammation markers, itoleucon 6 and tumor necrosis factor alpha.
- 9:25SPEAKER_00: The fire was successfully put out, or at least dampened, in the rat models.
- 9:28SPEAKER_00: The Foreman's instructions were received and followed.
- 9:31SPEAKER_01: The laboratory data in rodents is indeed robust.
- 9:35SPEAKER_01: However, the human data presents a stark contrast.
- 9:39SPEAKER_01: Out of the 52 studies reviewed, there were only three small randomized human trials.
- 9:44SPEAKER_00: Across all three trials, there were exactly 86 people involved in total.
- 9:49SPEAKER_01: Just 86 people.
- 9:50SPEAKER_01: Two of these trials utilized the bone marrow cells we mentioned earlier.
- 9:54SPEAKER_01: The follow-up periods for the patients in these trials were relatively short, ranging from about 12 weeks to 72 weeks.
- 10:01SPEAKER_00: So what happened when the treatment moved from rats to those 86 human patients?
- 10:05SPEAKER_00: Did the markers drop?
- 10:07SPEAKER_01: The results were highly disappointing.
- 10:09SPEAKER_01: In those human trials, there was no significant change in the measured inflammation marker.
- 10:14SPEAKER_00: There was no change in the creatinine levels, and there was no change in the kidney filtering rate.
- 10:20SPEAKER_01: The disease progression essentially continued.
- 10:22SPEAKER_01: The only possible biological signal they documented was lower albumin in the urine after treatment.
- 10:28SPEAKER_00: Aaron Powell That is a massive gap in the data.
- 10:30SPEAKER_00: We have 49 RAT studies showing a clear reduction in the fire versus just three human trials showing almost nothing.
- 10:37SPEAKER_00: I mean, is that single human result, the lower albumin in the urine, actually a meaningful clinical victory, or is it just a statistical blip when you are looking at a tiny pool of only 86 people?
- 10:48SPEAKER_01: Aaron Powell The authors of the review share your skepticism.
- 10:51SPEAKER_01: They explicitly state that the human evidence is completely inconclusive.
- 10:55SPEAKER_00: Aaron Powell Because when researchers attempt to pool results from a handful of small trials that feature differing trial designs, different cellular doses, and different cell sources.
- 11:04SPEAKER_01: The resulting numbers show a potential direction at best, rather than a definitive size of a treatment effect.
- 11:11SPEAKER_01: It is a known phenomenon in translational medicine.
- 11:14SPEAKER_01: A profound biological signal observed in an inbred laboratory rat can easily shrink or entirely vanish when introduced into the complex biology of humans.
- 11:24SPEAKER_00: Why does that happen, though?
- 11:25SPEAKER_00: Why do the four men succeed in a rat but fail in a human?
- 11:28SPEAKER_01: Aaron Powell Well, a laboratory rat is genetically homogenous, kept in a sterile environment, and given a standardized artificial kidney injury, which is often treated immediately.
- 11:39SPEAKER_00: Well, a human patient has unique genetics, years of complex environmental exposures, and a highly evolved immune system.
- 11:45SPEAKER_01: Aaron Ross Powell Plus, a human with CKD has likely been dealing with the underlying causes like hypertension or diabetes for decades.
- 11:54SPEAKER_00: So when the cellular foremin show up in a human body, the complex human immune system may simply ignore the chemical signals.
- 12:01SPEAKER_01: Aaron Ross Powell Or worse, view the administered cells as foreign debris and destroy them before they can even manage the environment.
- 12:08SPEAKER_00: Aaron Ross Powell With the human data being so sparse and inconclusive, where does this leave you, the listener, if you or a loved one is navigating a CKD diagnosis today?
- 12:17SPEAKER_01: Aaron Ross Powell It leaves you navigating a landscape of significant unknowns and calculated risks.
- 12:24SPEAKER_01: As we noted, the longest human trial in that rigorous review only tracked patients for 72 weeks.
- 12:30SPEAKER_00: Consequently, the long-term safety and the potential for long-term benefits are entirely unknown.
- 12:36SPEAKER_01: There is no universally standardized method for the dose required.
- 12:41SPEAKER_01: There is no consensus on the route of delivery, whether it is more effective to infuse the cells through a peripheral vein or directly into a renal artery.
- 12:50SPEAKER_00: Furthermore, any biological infusion carries inherent procedure risks, including the potential for a localized infection, filtering complications in the lungs, or an adverse immune reaction.
- 13:01SPEAKER_01: This uncertainty underscores why standard care remains the unshakable foundation for anyone with this condition.
- 13:07SPEAKER_00: Cellular research is a purely experimental frontier.
- 13:11SPEAKER_00: It absolutely does not replace the expertise of a kidney specialist, nor does it replace standard medical care.
- 13:17SPEAKER_01: Aaron Ross Powell The clinical guidelines from the NIDDK are unequivocal on the matter of standard care.
- 13:22SPEAKER_01: Strict blood pressure control is the single most important step a patient can take to slow the progression of chronic kidney disease.
- 13:30SPEAKER_00: And doctors typically manage this using specific medications like ACE inhibitors or ARBs, which ease the pressure on those delicate filtering vessels.
- 13:44SPEAKER_01: And I must state clearly that no treatment, experimental or standard, is known to cure chronic kidney disease.
- 13:52SPEAKER_00: Aaron Ross Powell We mentioned earlier that international patients frequently travel to explore these early treatments while maintaining their standard care regimens.
- 13:59SPEAKER_00: For instance, uh CeronaCell arranges treatment for its international patients at partner facilities in Kuala Lumpur.
- 14:05SPEAKER_01: Aaron Powell But any patient considering an international route for experimental procedures must ask rigorous, demanding questions.
- 14:13SPEAKER_00: The International Society for Stem Cell Research recommends investigating the specific source of the cells, demanding to see peer-reviewed clinical evidence rather than marketing material, and understanding exactly how patient safety and adverse events are being tracked over the long term.
- 14:28SPEAKER_01: Scrutinizing the details protects the patient.
- 14:31SPEAKER_01: It ensures they have a realistic understanding of the experimental nature of the intervention.
- 14:36SPEAKER_00: The stark contrast we discussed between the highly successful controlled animal data and the inconclusive variable human data demands that exact level of scrutiny from anyone stepping outside of standard clinical care.
- 14:56SPEAKER_00: The concept of introducing cellular formin to chemically manage the environment and lower the persistent inflammation shows genuine measurable promise in animal models.
- 15:06SPEAKER_01: However, the human evidence remains inconclusive, unproven, and strictly experimental.
- 15:13SPEAKER_00: The functional clinical tests, your blood creatinine and your estimated filtering rate, are still the most reliable metrics for managing the disease.
- 15:21SPEAKER_01: And standard medical care remains your primary proven defense against kidney decline?
- 15:26SPEAKER_01: The current data simply does not support altering or abandoning standard care based on these early cellular trials?
- 15:34SPEAKER_00: The laboratory promise has not yet translated into clinical reality.
- 15:38SPEAKER_00: When you look at the massive gap between the rats and the humans in these trials, it forces a larger perspective.
- 15:44SPEAKER_00: It makes you wonder: is the ultimate medical challenge really about finding the perfect cell source?
- 15:50SPEAKER_00: Or is it about learning how to translate the complex chemical language of a human immune system?
- 15:56SPEAKER_01: That is the pivotal question for the next decade of research.
- 16:00SPEAKER_00: Perhaps the future of treating chronic disease is not just about giving the body new biological materials, but finally learning how to speak its native language.
- 16:09SPEAKER_00: Thank you for joining us on this deep dive.
- 16:11SPEAKER_00: Keep asking the hard questions, demand good data, and we will catch you next time.